In this podcast, Dr. Neeraj Agarwal (US), presidential endowed chair of cancer research at the Huntsman Cancer Institute, University of Utah, shares the results of the LITESPARK-013 Phase 2 trial - "Safety and efficacy of two doses of belzutifan in patients with advanced renal cell carcinoma", that he presented at ESMO 2023.
Firstly, Dr. Agarwal shares the rationale of the study, which compared belzutifan 200mg and 120mg doses in patients with advanced clear cell RCC that progressed on anti-PD-1/L1 therapy to evaluate the safety and efficacy of these two doses in a larger, randomised trial.
Dr. Agarwal said that there was no difference in efficacy outcomes of belzutifan 200 mg and 120 mg orally once daily. Progression-free survival and overall survival were similar, as were the safety profiles between the two doses.
But, according to Dr. Neeraj, when they took a deep dive into the belzutifan 200mg once daily dose, it was associated with a higher rate of overall dose modifications and drug discontinuation. Based on these results, he concluded that belzutifan 120mg once daily dose in patients with clear cell RCC should remain the dose.